The HemOnc Pulse
The HemOnc Pulse
Advertisement
Chadi Nabhan, MD, MBA, FACPAggressive B-Cell Lymphoma | September 14, 2023
Jonathan Friedberg, MD, MMSc, discusses the trial and its implications for the field.
Listen Now
Chadi Nabhan, MD, MBA, FACPMeeting News | September 13, 2023
Dr. Garcia-Manero discusses key data from the phase III COMMANDS trial.
Chadi Nabhan, MD, MBA, FACPChronic Lymphocytic Leukemia | August 24, 2023
Dr. Shadman rounds up the latest news on CLL from the summer conferences in this episode of The HemOnc Pulse.
Chadi Nabhan, MD, MBA, FACPAcute Myeloid Leukemia | August 10, 2023
The changes brought about by molecular characterization have a profound impact on real-world clinical care for AML.
Chadi Nabhan, MD, MBA, FACPChronic Lymphocytic Leukemia | July 27, 2023
Nitin Jain, MD, discusses the data on venetoclax combinations in CLL and key frontline treatment considerations.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | July 13, 2023
Dr. Nowakowski discusses the L-MIND study and the "revolution in the treatment of DLBCL" in recent years.
Advertisement
Chadi Nabhan, MD, MBA, FACPAcute Myeloid Leukemia | June 29, 2023
Naveen Pemmaraju, MD, discusses the rare, ultrarare, and forgotten blood cancers on this episode of The HemOnc Pulse.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | June 15, 2023
Dr. Majhail explores strategies to improve access to CAR-T therapy.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | May 18, 2023
Drs. Vijenthira and Prica discuss their study and why its results differed from a similar study published in late 2022.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | May 4, 2023
Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma and key MRD considerations.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 20, 2023
Alan Skarbnik, MD, of Novant Health, discusses treating patients with follicular lymphoma and the nuances involved.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 6, 2023
Amer Zeidan, MBBS, MHS, of Yale, discusses the impact of AML classification updates and treatment considerations.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 23, 2023
Drs. Kambhampati and Thiruvengadam discuss their study investigating the cost effectiveness of pola-R-CHP in DLBCL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 9, 2023
Graham Collins, MD, discusses how to navigate the latest research in Hodgkin lymphoma.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 23, 2023
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 9, 2023
Dr. Sehn also explains why the TRIANGLE study is anticipated to change practices surrounding transplant in MCL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 26, 2023
Sanam Loghavi, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about why 2022 was a major year for MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 12, 2023
In this episode, Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, about CLL highlights from ASH 2022.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | December 29, 2022
Ruben Mesa, MD, discusses his career in MPN treatment and research and notable abstracts at the 2022 ASH Annual Meeting.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | December 14, 2022
In the inaugural episode of The HemOnc Pulse, Chadi Nabhan, MD, MBA, FACP, hosts Hagop Kantarjian, MD, and Elias Jabbour, MD.
Advertisement
Advertisement
Editorial Board